A Phase 1/2 interventional study of Vorinostat and Vorinostat in Carcinoma, Non-Small-Cell Lung, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2006, is one of 4 in phase 1/2, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 9 · Phase 3 1
First in 2001; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 21 across the 19 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 82nd largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2006, is one of 4 in phase 1/2, and was the 6th registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The reason for this study will be to find the safest maximum tolerated dose of oral vorinostat in combination with erlotinib [Tarceva (TM)] that can be given to patients with lung cancer who have relapsed or failed other therapy for the disease. Once the safest maximum tolerated dose of vorinostat is determined, patients enrolled in the clinical trial will continue vorinostat and erlotinib for up to 8 months. Safety and effectiveness will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion
Drug: Vorinostat · Drug: erlotinib
Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
Drug: Vorinostat · Drug: erlotinib
Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
Drug: Vorinostat · Drug: erlotinib
Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.
Drug: Vorinostat · Drug: erlotinib
Vorinostat 200 mg twice a day for 3 days a week.
Also known as: MK0683, Zolinza®
Vorinostat 300 mg once a day for 3 days a week.
Also known as: MK0683, Zolinza®
Vorinostat 300 mg twice a day for 3 days a week.
Also known as: MK0683, Zolinza®
Vorinostat 400 mg once a day for 21 out of 28 days.
Also known as: MK0683, Zolinza®
erlotinib 150 mg once a day.
Also known as: Tarceva ®
Dose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study
Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase I portion of the study.
Time frame: Day 1 to 28 in the Phase I portion of the study
Dose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study
Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase II portion of the study.
Time frame: Day 1 to 28 in the Phase II portion of the study
Unconfirmed Partial Response (UPR) Based on Response Criteria in Solid Tumors (RECIST)
An unconfirmed partial response is defined as a partial response that has not been confirmed by a follow up CT scan (or MRI) at least 4 weeks after the criteria for response are first met. (A partial response is defined as an at least 30% reduction in the sum of the longest diameter of the target lesions. Non-target lesions must be at least stable)
Time frame: Every 57 days beginning with Cycle 3, or more frequently if appropriate
Stable Disease (SD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)
Stable disease is defined as less than a radiographic partial response, but not progressive disease
Time frame: Every 57 days beginning with Cycle 3, or more frequently if appropriate
Progressive Disease (PD) as Best Response Based on Response Criteria in Solid Tumors (RECIST)
Progressive disease is defined as a ≥20% increase in the sum of the longest diameter, the appearance of one or more new lesions and/or unequivocal progression of non-target lesions by conventional or spiral CT or MRI
Time frame: Every 57 days beginning with Cycle 3, or more frequently if appropriate
Disease Progression After Week 8 Based on Response Criteria in Solid Tumors (RECIST)
First documentation of Progressive Disease (PD) occurring \> 8 weeks on study.
Time frame: Every 57 days beginning with Cycle 3 (Week 8), or more frequently if appropriate
Progression-free Survival
Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded).
Time frame: Day 1 to disease progression or death
This study was conducted at 12 investigative sites in the United States. The first patient's first visit was 30 March 2006. The study was terminated early on 12 Oct 2007 and the last patient's last visit was 30 Oct 2007.
| Milestone | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Started | 16 | 3 | 2 | 2 |
| Completed | 1 | 0 | 0 | 0 |
| Not completed | 15 | 3 | 2 | 2 |
| Withdrew: Adverse event | 5 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Withdrew: Discontinued due to progressive disease | 9 | 1 | 0 | 1 |
Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase I portion of the study.
| Participants | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Dose Limiting Toxicity (DLT) Occurring in Cycle 1 of the Phase I Portion of the Study | 0 | 2 | 2 | 1 |
An unconfirmed partial response is defined as a partial response that has not been confirmed by a follow up CT scan (or MRI) at least 4 weeks after the criteria for response are first met. (A partial response is defined as an at least 30% reduction in the sum of the longest diameter of the target lesions. Non-target lesions must be at least stable)
| Participants | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Unconfirmed Partial Response (UPR) Based on Response Criteria in Solid Tumors (RECIST) | 0 | 0 | 0 | 0 |
Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycle 1 of the Phase II portion of the study.
| Participants | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Dose Limiting Toxicity Occurring in Cycle 1 of the Phase II Portion of the Study | 3 | — | — | — |
Adverse event(s) that determined the treatment dose level was not tolerable for that patient in Cycles 2 and beyond of the Phase II portion of the study.
| Participants | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Dose Limiting Toxicity Occurring in Cycles 2 and Beyond of the Phase II Portion of the Study | 3 | — | — | — |
Stable disease is defined as less than a radiographic partial response, but not progressive disease
| Participants | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Stable Disease (SD) as Best Response Based on Response Criteria in Solid Tumors (RECIST) | 6 | 1 | 1 | 1 |
Progressive disease is defined as a ≥20% increase in the sum of the longest diameter, the appearance of one or more new lesions and/or unequivocal progression of non-target lesions by conventional or spiral CT or MRI
| Participants | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Progressive Disease (PD) as Best Response Based on Response Criteria in Solid Tumors (RECIST) | 7 | 0 | 0 | 0 |
First documentation of Progressive Disease (PD) occurring \> 8 weeks on study.
| Participants | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| Disease Progression After Week 8 Based on Response Criteria in Solid Tumors (RECIST) | 3 | 0 | 0 | 0 |
Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded).
| Days | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|
| Progression-free Survival | 57 (26 to 113) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | — | 6/16 (37.5%) | 16/16 (100%) |
| Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | — | 2/3 (66.7%) | 3/3 (100%) |
| Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | — | 2/2 (100%) | 2/2 (100%) |
| Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk | — | 1/2 (50%) | 2/2 (100%) |
| Event | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/16 | 0/3 | 1/2 | 0/2 |
| Cerebral ischaemiaNervous system disorders | 0/16 | 0/3 | 0/2 | 1/2 |
| Deep vein thrombosisVascular disorders | 0/16 | 0/3 | 1/2 | 0/2 |
| Confusional statePsychiatric disorders | 0/16 | 1/3 | 0/2 | 0/2 |
| Exfoliative rashSkin and subcutaneous tissue disorders | 0/16 | 1/3 | 0/2 | 0/2 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/16 | 0/3 | 0/2 | 0/2 |
| NauseaGastrointestinal disorders | 1/16 | 0/3 | 0/2 | 0/2 |
| VomitingGastrointestinal disorders | 1/16 | 0/3 | 0/2 | 0/2 |
| InfectionInfections and infestations | 1/16 | 0/3 | 0/2 | 0/2 |
| Pneumococcal bacteraemiaInfections and infestations | 1/16 | 0/3 | 0/2 | 0/2 |
| Event | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/16 | 1/3 | 0/2 | 2/2 |
| DiarrhoeaGastrointestinal disorders | 13/16 | 3/3 | 2/2 | 2/2 |
| NauseaGastrointestinal disorders | 13/16 | 2/3 | 2/2 | 2/2 |
| VomitingGastrointestinal disorders | 6/16 | 1/3 | 2/2 | 2/2 |
| FatigueGeneral disorders | 8/16 | 1/3 | 0/2 | 2/2 |
| Weight decreasedInvestigations | 6/16 | 1/3 | 2/2 | 1/2 |
| RashSkin and subcutaneous tissue disorders | 9/16 | 3/3 | 0/2 | 2/2 |
| AnorexiaMetabolism and nutrition disorders | 10/16 | 1/3 | 1/2 | 0/2 |
| PhotopsiaEye disorders | 0/16 | 0/3 | 0/2 | 1/2 |
| Breath odourGastrointestinal disorders | 0/16 | 0/3 | 0/2 | 1/2 |
| Age, Continuous(Years) | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk | Total |
|---|---|---|---|---|---|
| Mean | 53.0 ± 4.36 | 66.0 ± 8.49 | 48.5 ± 20.51 | 59.1 ± 11.59 | 60.7 ± 11.41 |
| Age, Customized(Participants) | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk | Total |
|---|---|---|---|---|---|
| ≤ 65 years | 11 | 3 | 1 | 2 | 17 |
| > 65 years | 5 | 0 | 1 | 0 | 6 |
| Sex: Female, Male(Participants) | Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk | Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk | Total |
|---|---|---|---|---|---|
| Female | 8 | 2 | 1 | 1 | 12 |
| Male | 8 | 1 | 1 | 1 | 11 |
No study locations are listed for this record.
The record gives a start of Jan 2006, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat
Carcinoma, Non-Small-Cell Lung →